Marstacimab

Hympavzi

150MG/ML InjectionUnited StatesMarketedAuthorised 11 Oct 2024

In other countries

The same active substances on other registers, the same brand first.

HympavziBrazil · Pfizer Brasil LtdaSame brand
Hympavzi 150 MG Solucion Inyectable en Pluma PrecargadaSpain · 150 mg · solución inyectable en pluma precargada · Pfizer Europe Ma EeigSame brand
HympavziEuropean Union · Pfizer Europe MA EEIGSame brand
HympavziCroatiaSame brand
HympavziItaly · Soluzione iniettabile in penna pre-riempita · Pfizer Europe Ma EeigSame brand
Hympavzi 150 mg oplossing voor injectie in een voorgevulde penNetherlands · Oplossing voor injectie · Pfizer Europe MA EEIGSame brand
Hympavzi 150 mg oplossing voor injectie in een voorgevulde spuit

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Marstacimab

Hympavzi

150MG/ML InjectionUnited StatesMarketedAuthorised 11 Oct 2024

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Netherlands · Oplossing voor injectie · Pfizer Europe MA EEIG

Hympavzi Solution for Injection in Single-Dose Pre-Filled Pen 150 MG/MLSingapore · 150 mg/ml · injection, solution · Pfizer Private Limited

Documents

The official texts, at the regulator.

Register entryFDA

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

U.S. Food and Drug Administration

FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.

Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions · Added 11 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Marstacimab
Strength: 150MG/ML
Dosage form: Injection
Route: Subcutaneous
Register: United States (FDA)
Status: Marketed
Status in the register: Licensed / Rx
Authorised: 11 Oct 2024
Registration: BLA 761369
Marketing authorisation holder: Pfizer Inc.
Procedure: 351(a)
Supply: Rx

FDA

HympavziMarstacimab · 300MG · injectableUnited States